Literature DB >> 27251672

[Individualized treatment of osteoporosis].

B Harbeck1, H Lehnert2.   

Abstract

Osteoporosis is the most common clinical disorder of bone metabolism. Treatment decisions should be made on an individual basis, taking into consideration the relative benefits and risks in different patient populations. Drug selection should be based on the form (primary/secondary) and severity of osteoporosis, age, sex, the specific contraindications and precautions for using the various available medications, and existing comorbidities.

Entities:  

Keywords:  Age factors; Comorbidity; Fracture prophylaxis; Osteoporosis, drug therapy; Risk assessment

Mesh:

Substances:

Year:  2016        PMID: 27251672     DOI: 10.1007/s00108-016-0074-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

Review 1.  Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review.

Authors:  Erik F Eriksen; Adolfo Díez-Pérez; Steven Boonen
Journal:  Bone       Date:  2013-10-09       Impact factor: 4.398

Review 2.  Clinical Practice. Postmenopausal Osteoporosis.

Authors:  Dennis M Black; Clifford J Rosen
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245

3.  The epidemiology of osteoporosis--Bone Evaluation Study (BEST): an analysis of routine health insurance data.

Authors:  Peyman Hadji; Silvia Klein; Holger Gothe; Bertram Häussler; Thomas Kless; Torsten Schmidt; Thomas Steinle; Frank Verheyen; Roland Linder
Journal:  Dtsch Arztebl Int       Date:  2013-01-25       Impact factor: 5.594

4.  Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial.

Authors:  Susan L Greenspan; Subashan Perera; Mary Anne Ferchak; David A Nace; Neil M Resnick
Journal:  JAMA Intern Med       Date:  2015-06       Impact factor: 21.873

5.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

6.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

7.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

8.  Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.

Authors:  Ibrahim A Abdelazim; Khaled M Abdelrazak; Mohamed Al-Kadi; Amr H Yehia; Bassam M Sami Nusair; Mohannad Abu Faza
Journal:  Arch Osteoporos       Date:  2014-07-19       Impact factor: 2.617

Review 9.  Use of teriparatide in osteoporotic fracture patients.

Authors:  Cory Collinge; Juan Favela
Journal:  Injury       Date:  2016-01       Impact factor: 2.586

Review 10.  New insights into treatment of osteoporosis in postmenopausal women.

Authors:  Piet Geusens
Journal:  RMD Open       Date:  2015-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.